SK Securities published a company analysis report on EOFlow today on 22/07/2021.
Analyst Lee commented that EOFlow's wearable disposable insulin pump was sold in Korea from 1Q21 and with national healthcare insurance, sales in EOFlow is expected to increase greatly. He also commented that the Company acquired European CE mark and plan to launch the product in Europe in 3Q21. He mentioned that the Company is also considering a partnership to establish a JV in China.
Attached is a report titled "Expecting sales increase in 2022" (only in Korean).